Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Novachor is a fresh human placental allograft wound covering composed of unaltered chorion membrane derived from donated birth tissue and preserved hypothermically to maintain viable cells, native extracellular matrix, growth factors, cytokines, and structural proteins.[5][7][9][12] Developed and commercialized by Organogenesis for advanced wound care and surgical/sports medicine applications, it is used as a protective barrier and extracellular matrix scaffold to support the body’s inherent healing processes in a variety of partial- and full-thickness acute and chronic wounds, including those with exposed tendon, muscle, joint capsule, or bone.[2][4][5][6][7][10][12] As a biologic tissue allograft rather than a traditional pharmaceutical, its therapeutic effect is mediated by providing a biologically active matrix that modulates the wound environment, rather than by receptor-targeted pharmacologic action.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Novachor.